<DOC>
	<DOC>NCT00549692</DOC>
	<brief_summary>The purpose of this study is to compare omega-3 fatty acids with placebo for efficacy in retardation of increase of serum creatinine(SCr) in IgA Nephropathy</brief_summary>
	<brief_title>Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy</brief_title>
	<detailed_description>In the current clinical study, attempts are made to assess the safety and efficacy of omega-3 fatty acids by comparing between omega-3 fatty acids and the placebo in Korean patients with IgA nephropathy.</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis, IGA</mesh_term>
	<criteria>Patient of both sexes age 18 or above Biopsyproven IgA nephropathy Baseline serum creatinine ≥ 1.2mg/dl(Female),≥ 1.4mg/dl(Male) Able to give written informed consent Hypertension SBP&gt;160mmHg and/or DBP&gt;100mmHg Subject, who in the investigator's opinion, has a systemic disease that would contraindicate participation in this study Use of omega3 fatty acids or analog supplement Pregnancy or breast feeding at time of entry or unwillingness to comply with measures for contraception Current or recent (within 30 days) exposure to any investigational drug Subject who has hypersensitivity to this agent as a previous illness Low platelet(&lt;100,000/㎕) or the subject who has a high risk of bleeding Use of corticosteroid during the treatment period or less than 3 months prior to the screening Use of anticoagulant during the treatment period or within 1 month or 6 half lives prior to screening Subject who in the investigator's opinion, would be confronted with a difficulty</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>